Clinical Trial Update: Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT. [Phase 2]

View source ↗

Summary

Phase 2 trial investigating emapalumab for pre-empting graft failure after hematopoietic stem cell transplantation; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft Failure After Hematopoietic Stem Cell Transplantation

Drugs mentioned

• Emapalumab (emapalumab)

Snippet

Sponsor: Swedish Orphan Biovitrum | Conditions: Graft Failure | Phase 2 | Status: TERMINATED | Results posted: 2023-12-28